Influence of SGLT2-inhibitor (Canagliflozin) in patients with DM who underwent cardiac surgery
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2018
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 26 Mar 2018 Status changed from active, no longer recruiting to completed.
- 01 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Nov 2016 Planned number of patients changed from 20 to 30.